Lu
Yong, an oncologist, and his team are going to launch new method to treat
patients with lung cancer. Their plan is to carry out clinical trials of
injecting patients to modify their cells with CRSIPR-Cas9 during clinical
trials. This would be a great new method to use since there are many patients
who experience chemotherapy in vain because the treatment is ineffective. The
team of oncologist plan to execute the new procedure by first extracting T
cells from the patient and then use the CRSIPR-Cas9 technology. The CRSIPS-Cas9
technology is used by snipping chromosomes which gets rid of genes at a
specific point. This in turn allows the body to begin to produce cells that
help the immune system of patients. Once this is done the cells are then
replicated in a laboratory. Although CRSIPR-Cas9 is known to be harmful if the
wrong genes are taken away from the chromosome the team of oncologist will reassure
themselves that the procedure went expected before placing the gene edited
cells in the patients. CRSIPR-Cas9 is a cheap, quick and easy way to do gene
editing in the laboratory. However, there has been cases when the ethics of
this method were questioned. For example, the genes of an embryo were used but
when it was placed back in the embryo it did not survive. Questions were raised
whether or not this method could throw off whole ecosystems. This method regardless
of certain flaws gives scientist the power to change human genomes and cure
diseases.
Although,
there are possible risk with the CRSIP-Cas9 method there is even a greater risk
if patients are not given more options to help combat cancer. If chemotherapy
is not working then it would best to try anything else that could possibly work
to save a person’s life. Medicine is about practice to determine what new
innovative ways physicians can save someone’s life.
No comments:
Post a Comment